Nitrofix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrofix

Understanding Nitrofix

Nitrofix is a medication primarily used in the management and prevention of angina pectoris, a type of chest pain caused by reduced blood flow to the heart muscle. It belongs to a class of drugs known as nitrates, which work by relaxing and widening blood vessels.

Mechanism of Action

The active therapeutic process involves the dilation of both arteries and veins. By widening the blood vessels, Nitrofix reduces the workload on the heart, making it easier for the heart to pump blood. Additionally, this dilation improves the supply of oxygen-rich blood to the heart muscle, which helps to prevent the onset of chest pain during physical activity or stress.

Therapeutic Use

Nitrofix is specifically designed for the long-term prevention of angina attacks. It is important to note that this medication is a prophylactic treatment, meaning it is intended to be taken regularly to reduce the frequency and severity of symptoms over time. Because of its mechanism of action, it is not used to treat an acute or sudden onset of chest pain that has already begun.

Formulation and Characteristics

As a nitrate-based therapy, Nitrofix is available in formulations that allow for a steady release of the medication into the bloodstream. This consistency is vital for maintaining the necessary levels of the drug to provide continuous cardiovascular support throughout the day. Its use is focused on stabilizing heart function and improving the quality of life for individuals with chronic stable angina.

Regulatory References

  1. MedlinePlus: Isosorbide Mononitrate Drug Information

What side effects are possible with Nitrofix?

Possible Side Effects and Safety Information

The safety profile for Nitrofix (Isosorbide Mononitrate) is based on official government regulatory documents (e.g., FDA, EMA SmPC), which categorize adverse reactions by frequency and affected body system. This information is descriptive and not intended as medical advice.

Adverse Reactions by Frequency

The following are the common and serious adverse reactions documented in the official prescribing information:

Frequency System Organ Class Adverse Reaction
Very Common Nervous System Disorders Headache (often diminishing with continued use)
Common Vascular Disorders, Cardiac Disorders Hypotension (Low Blood Pressure), Tachycardia (Increased Heart Rate)
Common Nervous System Disorders, GI Disorders Dizziness, Nausea
Uncommon GI Disorders Vomiting, Diarrhea, Heartburn
Rare Blood and Lymphatic System Disorders Methaemoglobinaemia

Serious Adverse Reactions and Restrictions

Official labeling identifies several clinically important risks and constraints:

  • Serious Adverse Reactions: These include Severe Hypotension (potentially leading to circulatory collapse or syncope) and the rare blood disorder Methaemoglobinaemia.
  • Contraindications: Nitrofix is strictly contraindicated in patients with marked low blood pressure (e.g., systolic pressure le 90 mmHg) and acute circulatory failure (shock). It is also strictly forbidden for use with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil) due to the risk of severe, life-threatening hypotension.

Population-Specific Safety Notes

Caution is advised for specific patient groups:

  • Elderly and Impaired Patients: Caution is advised due to the increased risk of severe low blood pressure and potential for altered drug handling in those with severe hepatic or renal impairment.
  • Pregnancy and Pediatric Use: The safety and effectiveness of Isosorbide Mononitrate have not been established for use during pregnancy, lactation, or in pediatric patients.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Nitrofix (Isosorbide Mononitrate) can result in severe, potentially life-threatening clinical manifestations, primarily due to extreme vasodilation. Regulators explicitly state that an overdose can be fatal and requires immediate emergency medical attention.

Documented Overdose Manifestations

The official labeling documents the following signs upon exposure to substantially greater than recommended doses:

  • Cardiovascular: Profound hypotension (low blood pressure), syncope (fainting), reflex tachycardia, palpitations, and, rarely, paradoxical bradycardia.
  • Neurological: Severe throbbing headache, confusion, vertigo, visual disturbances, and the potential for convulsions (seizure).
  • Systemic Risk: The potential for Methemoglobinemia is documented, a condition requiring specific intervention, and is associated with circulatory failure.

Emergency Actions and Management

Upon any suspected overdose, individuals must seek emergency medical attention or call the Poison Help line immediately. Management is symptomatic and supportive, as no specific antagonist to the severe vasodilator effects is known.

Treatment is directed toward increasing central fluid volume, which may involve methods such as the passive elevation of the patient's legs and intravenous fluid infusion. Monitoring of blood pressure and pulse, along with observation for at least 12 hours, is required. Treatment is noted as being particularly subtle and difficult for patients with pre-existing renal disease or congestive heart failure, for whom invasive monitoring may be required.

Therapeutic Uses of Nitrofix

What Nitrofix Treats: Main Uses and Benefits

Nitrofix (Isosorbide Mononitrate) is generally used as a long-term treatment strategy focused on providing continuous supportive relief for established cardiovascular conditions. The primary goal is prophylactic—the medication may be part of a long-term strategy to manage symptoms related to physical discomfort of heart strain, rather than being applied to address an active, acute symptomatic event. The medication is commonly used to help with the prevention of chest pain (angina) caused by coronary artery disease.


Prophylaxis and Symptom Management

This therapeutic domain is commonly used for managing Chronic Angina Pectoris, a condition characterized by recurrent episodes of chest discomfort, pressure, or tightness. It is applied in clinical settings where adult patients with Coronary Artery Disease require long-term support. The medication may assist with managing the frequency and severity of symptoms associated with these episodic anginal attacks.


Managing the Symptom Burden of Cardiovascular Strain

Nitrofix provides supportive relief and may help ease the overall symptom load. The medication may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Recurrent Chest Discomfort The primary role is in managing the recurrence and reducing the symptomatic intensity of episodic anginal manifestations, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Nitrofix (isosorbide mononitrate) is typically prescribed to prevent heart-related chest pain (angina pectoris) but is not used to treat a sudden, acute anginal attack.

Who Should NOT Use Nitrofix?

Nitrofix is contraindicated in several patient groups due to the risk of severe side effects, especially a dangerous drop in blood pressure. Crucially, it must never be taken with medicines used for erectile dysfunction or pulmonary hypertension, such as sildenafil, tadalafil, or vardenafil, as this combination can cause severe hypotension (low blood pressure) and collapse.

Patients with the following conditions should not use this medication:

  • Allergy to isosorbide mononitrate or any other nitrates.
  • Severe hypotension (very low blood pressure).
  • Acute circulatory failure (shock or vascular collapse).
  • Certain heart conditions, including hypertrophic obstructive cardiomyopathy, constrictive pericarditis, or severe aortic/mitral valve stenosis.
  • Severe anemia (low red blood cell count).
  • Conditions causing increased pressure inside the head (e.g., recent head trauma or cerebral hemorrhage).

Nitrofix should be used with extreme caution and only under a doctor's guidance in individuals who are pregnant, breastfeeding, or have pre-existing conditions like severe kidney or liver impairment, low body temperature (hypothermia), or elevated pressure in the eyes (closed-angle glaucoma).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for Nitrofix (Isosorbide Mononitrate) based on authoritative government regulatory labeling.

Absolute Restrictions (Contraindicated Combinations)

Co-administration with Phosphodiesterase Type 5 (PDE-5) Inhibitors is strictly contraindicated. This prohibition applies to medicines such as Sildenafil, Tadalafil, and Vardenafil. The documented outcome of this combination is a severe, potentially life-threatening potentiation of the vasodilatory effect, leading to profound systemic hypotension.

Pharmacodynamic Interactions

Nitrofix is documented to interact with other substances that lower blood pressure, resulting in an additive hypotensive effect. This pharmacodynamic interaction is relevant when co-administered with other Antihypertensive Agents, including Calcium Channel Blockers, Beta-blockers, and Diuretics. The regulatory profile notes that co-ingestion of alcohol also enhances the vasodilating action, contributing to an increased risk of hypotension.

Interaction Type Interacting Substance/Class Official Interaction Statement
Contraindicated PDE-5 Inhibitors Absolute prohibition; risk of severe hypotension
Additive Effect Antihypertensive Agents Documented risk of enhanced hypotensive effect
Substance Interaction Alcohol Enhances vasodilating action and hypotension risk

No clinically significant pharmacokinetic interactions, such as those involving the Cytochrome P450 enzyme system, are formally documented in regulatory labels as affecting the active substance's exposure. The restrictions are primarily focused on preventing synergistic effects on vascular tone.

Mechanism of Action

How Nitrofix Works

Bioactivation and the Nitric Oxide Pathway

The action of Isosorbide Mononitrate (Nitrofix) is purely based on its pharmacodynamic ability to modulate vascular tone through a specific molecular pathway. Nitrofix functions as a prodrug that must be enzymatically reduced inside vascular smooth muscle cells to release Nitric Oxide (NO). The released NO subsequently activates the enzyme soluble Guanylyl Cyclase (sGC), initiating the core intracellular cascade.

Cascade to Smooth Muscle Relaxation

The activated sGC enzyme increases levels of the messenger cGMP, which drives the dephosphorylation of muscle proteins. This chemical sequence interrupts the contraction cycle of the smooth muscle tissue, resulting in widespread vasodilation (vessel widening).

Modulating Systemic Hemodynamics

This vasodilation preferentially relaxes the large veins (venodilation), which significantly lowers the pressure and volume of blood returning to the heart (preload reduction). This action, combined with reduced resistance in arterioles (afterload reduction), is the physiological mechanism responsible for decreasing myocardial oxygen demand.

Dosage and Administration Information

The administration of Nitrofix (Isosorbide Mononitrate) is governed by specific instructions for its long-term, prophylactic use. The standard route of administration for all available forms, including Immediate-Release (IR) and Extended-Release (ER) tablets, is oral.

Key Administration Directives

Category Official Instruction
Dosing & Frequency The dosing schedule is defined to maintain a necessary nitrate-free interval daily, typically 10 to 12 hours. Immediate-Release doses are taken asymmetrically (e.g., 7 hours apart), while the Extended-Release formulation is taken once daily in the morning. Starting doses range from 5 mg to 60 mg depending on the specific product form and prescribed frequency.
Preparation & Constraints ER tablets must not be crushed, chewed, or split; they must be swallowed whole to preserve the controlled-release mechanism. IR tablets should be taken on an empty stomach.
Population Rules For older adults, official instructions require initiating treatment at the low end of the dosage range. The safety and efficacy of the medicine are not established for use in pediatric patients.
Use Duration Nitrofix is used as a long-term prophylactic strategy. Discontinuation of therapy must occur gradually—the dose and frequency must be tapered and should not be stopped suddenly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitrofix

Evidence for Use in Chronic Stable Angina Pectoris

Nitrofix (Isosorbide Mononitrate) was studied in research exploring symptom patterns in Chronic Stable Angina Pectoris, a condition characterized by fluctuating manifestations of chest discomfort due to heart disease. Research explored whether outcomes differed in patients who received Nitrofix compared to those who received a placebo in Randomized Controlled Trials (RCTs). These trials were typically short-term, lasting a few weeks up to six weeks.

In these studies, studies monitored outcomes related to the frequency of anginal attacks and the recorded rate of use of faster-acting relief medications. Research examined functional capacity by measuring total exercise time and the time elapsed before symptoms appeared during a stress test. A key area of research focus was studied for the potential development of tolerance, which involves a measured decrease in the pharmacologic effect over time with continuous administration. Research does not determine whether an individual will respond similarly to the group patterns observed in these studies.


Evidence for Adjunctive Use in Systolic Hypertension

Nitrofix was studied for its use in Systolic Hypertension, often in conjunction with other established treatments. The studies involved specific patient groups, predominantly elderly adults with long-standing, often complex, blood pressure conditions. Studies explored outcomes related to systemic or functional imbalance by measuring changes in systolic blood pressure (SBP) and examining outcomes monitoring physiological strain by looking at measurements related to the stiffness of the arteries.

However, the results apply only to the populations studied, meaning the data for certain groups remain insufficient for general conclusions. The research landscape is characterized by a lack of comparative evidence against many standard blood pressure treatments.


Research Gaps and Areas of Uncertainty

Evidence for long-term outcomes remains limited for major events such as heart attacks or mortality. While some studies in the context of high blood pressure were observed in some studies to have extended follow-up, the core antianginal research is not designed to track these major outcomes over similarly extended periods. The research landscape is characterized by a lack of comparative evidence for how the drug performs against other available treatments.

Key Studies & References

  1. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF) trial (used for evidence gap and absence of efficacy in non-angina setting)

Frequently Asked Questions (FAQ)

Common questions about Nitrofix (FAQ)

Q: How quickly does Nitrofix usually start working?

A: According to official product information, the active substance is absorbed rapidly by the body. It typically reaches its maximum concentration in the bloodstream within 30 to 60 minutes after taking the Immediate-Release form. This measurement describes when the medicine is most available to exert its intended action.


Q: Can Nitrofix cause drowsiness or affect daily activities?

A: Official information documents dizziness and headache as common side effects. These effects may influence activities that require concentration or physical coordination. In situations where a person experiences dizziness, caution regarding activities is generally noted as appropriate.


Q: How long does Nitrofix stay in the system after the last use?

A: The half-life of the active substance in Nitrofix is approximately five hours. The half-life describes the time it takes for half of the substance to be eliminated from the body. The medicine’s presence in the body gradually decreases as the substance is processed.


Q: Is it normal to feel a mild stomach discomfort when first starting Nitrofix?

A: Gastrointestinal issues, such as nausea and heartburn, are listed as common or uncommon adverse reactions in official safety documents. These types of discomfort are noted as potential experiences for persons using the medicine.


Q: What is the most frequently reported side effect of Nitrofix?

A: Official documents list headache as a Very Common side effect, meaning it is one of the most frequently reported. Official information indicates that this effect often lessens or resolves with continued use.


Q: Does Nitrofix need to be taken with food?

A: Regulatory instructions state that the Immediate-Release tablet should be taken on an empty stomach. For the Extended-Release form, the official product information does not contain a specific restriction regarding food consumption.


Q: Is Nitrofix the same type of medicine as [similar drug name]? How are they generally different?

A: Nitrofix is classified as an Organic Nitrate Vasodilator. Official sources indicate this class of medicine is primarily used for its effects on modifying blood vessel tone. Other medicines belonging to the organic nitrate class have their own distinct profiles and regulatory instructions.


Q: Can I take Nitrofix if I only have mild symptoms?

A: The approved purpose of Nitrofix is defined as the prophylactic (preventative) management of chronic stable chest pain. It is not approved for use in treating a sudden, acute anginal attack.


Q: How is Nitrofix eliminated from the body?

A: The active substance is largely processed (metabolized) in the liver. The resulting components are then eliminated from the body primarily through the kidneys.


Q: Why do some people report feeling [specific, non-severe side effect] when starting Nitrofix?

A: Official information notes that some effects, like headache, are common when starting treatment. These effects often diminish or resolve with continued, regular use as the body adjusts.


Q: Is it possible to take Nitrofix while traveling internationally?

A: Official storage instructions require that the medicine be kept at Controlled Room Temperature (typically between 15 C and 30 C). It must also be protected from excessive heat, moisture, and light during storage.


Q: Are there any special considerations for older adults using Nitrofix?

A: Regulatory instructions note that treatment for older adults should be initiated at the low end of the dosage range. Caution is also generally advised due to the increased potential for the medicine to cause low blood pressure in this population.


Q: Does regulatory information mention any known interactions between Nitrofix and common herbal supplements?

A: Regulatory labels focus on documented interactions with other prescription medicines, especially those that also lower blood pressure. Official documents do not typically contain specific, conclusive interaction statements for all common herbal supplements.


Q: Is it considered a 'rescue medicine' or something taken regularly?

A: Official sources describe Nitrofix as being used for the long-term prophylactic (preventative) management of chronic chest pain. This means it is intended for regular, preventative use rather than acute, immediate relief.


Q: What evidence is available from clinical trials about Nitrofix?

A: Clinical trials have explored the medicine's effects in reducing the frequency of anginal attacks and measuring improvement in exercise tolerance. This research is used to support the approved uses of the drug.


Q: Does Nitrofix affect blood pressure?

A: Yes, its primary function is to widen blood vessels, which lowers blood pressure. Hypotension (Low Blood Pressure) is listed as a common side effect and serious adverse reaction in official safety documents.


Q: Has there been any research on the use of Nitrofix in patients with kidney concerns?

A: Official labeling advises caution in patients with severe renal impairment (kidney concerns). This suggests that the potential for altered drug handling in this population is a factor that has been considered by regulators.


Q: Can Nitrofix be used alongside common over-the-counter pain medications?

A: Regulatory documents state warnings regarding pharmacodynamic interactions that could cause an additive hypotensive effect (further lowering blood pressure) when combined with other medicines. Official labels focus on interactions that result in an enhanced hypotensive effect.


Q: Why is timing important when taking Nitrofix?

A: The dosing schedule is specifically designed to include a necessary nitrate-free interval daily. This interval is required to help prevent the development of tolerance, which is a measured decrease in the pharmacologic effect over time.


Q: Are there alternatives that work similarly to Nitrofix?

A: The medicine is part of the organic nitrate drug class. Other medicines belonging to this class are also used for similar purposes in cardiovascular management.


Q: What happens if a regular dose of Nitrofix is generally missed?

A: Official patient information materials describe procedures for a generally missed dose, which includes instruction to not take a double dose. Specific handling of a missed dose should follow the product labeling.


Q: Is Nitrofix addictive or habit-forming?

A: Official documentation confirms that the active ingredient, Isosorbide Mononitrate, is not classified as a controlled substance. The medicine is not considered to be addictive or habit-forming.


Q: What is the general recommendation regarding alcohol consumption and Nitrofix?

A: Official warnings state that co-ingestion of alcohol enhances the vasodilating action of the medicine. This combination contributes to an increased risk of severe low blood pressure (hypotension).


Q: Where can I find the most current official patient information about Nitrofix?

A: Official patient information and prescribing details are published and maintained on government websites. Examples include the U.S. National Library of Medicine (MedlinePlus) and the FDA’s (DailyMed) database.


Q: Do studies suggest any specific dietary requirements while taking Nitrofix?

A: The only specific direction regarding consumption is that the Immediate-Release tablet should be taken on an empty stomach. No other specific food-based requirements are noted in regulatory information.


Q: Can Nitrofix be safely combined with common antacids?

A: Regulatory labels do not typically document an interaction with common antacids. This generally suggests that no known or significant pharmacokinetic interaction is noted by the regulator.


Q: Are there specific patient groups where the benefits of Nitrofix may be greater?

A: Research has been explored in specific patient groups, such as the elderly with Systolic Hypertension. Regulatory documents report outcomes observed in various populations, including this group.


Q: Is it necessary to have ongoing monitoring while using Nitrofix?

A: Due to the potential for the medicine to cause hypotension (low blood pressure), monitoring of blood pressure is noted in regulatory warnings as a necessary caution, especially when initiating the medicine or adjusting the dosage.


Q: Why does the packaging say 'Prescription Only'?

A: The medicine is classified as a Prescription-Only Medicine (POM) because its potential for severe side effects, such as profound hypotension, requires the oversight of a qualified health professional to manage its use safely.

How should Nitrofix be stored and disposed of?

Storage and Disposal of Nitrofix (Isosorbide Mononitrate)

Nitrofix must be stored at Controlled Room Temperature, typically between 15 C and 30 C. It is mandatory to keep the medication in the tightly closed, original container and safely out of the sight and reach of children.

The medication must be protected from excessive heat, moisture, and light; therefore, storage in environments such as a bathroom is prohibited. The label specifies that the container should be kept from freezing.

For disposal, the official method for unused or expired tablets is utilizing a drug take-back program. If this option is not available, the FDA advises mixing the medicine with an undesirable substance before sealing it in a container and placing it in the household trash. Do not flush the tablets unless specifically instructed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrofix found in:

A-Z Index: